Characterization and Protective Activity of Monoclonal Antibodies Directed against Streptococcus suis Serotype 2 Capsular Polysaccharide Obtained Using a Glycoconjugate
Open Access
Abstract
Streptococcus suis serotype 2 is an encapsulated bacterium and an important swine pathogen. Opsonizing antibody responses targeting capsular polysaccharides (CPSs) are protective against extracellular pathogens. To elucidate the protective activity of monoclonal antibodies (mAbs) directed against S. suis serotype 2 CPS, mice were immunized with a serotype 2 CPS-glycoconjugate and three hybridomas were isolated; of which, two were murine IgMs and the other a murine IgG1. Whereas the IgMs (mAbs 9E7 and 13C8) showed different reactivity levels with S. suis serotypes 1, 1/2, 2 and 14, the IgG1 (mAb 16H11) was shown to be serotype 2-specific. All mAbs targeted the sialylated chain of the CPSs. Using an opsonophagocytosis assay, the IgMs were opsonizing towards the S. suis serotypes to which they cross-react, while the IgG1 failed to induce bacterial elimination. In a model of mouse passive immunization followed by a lethal challenge with S. suis serotype 2, the IgG1 and IgM cross-reacting only with serotype 14 (mAb 13C8) failed to protect, while the IgM cross-reacting with serotypes 1, 1/2, and 14 (mAb 9E7) was shown to be protective by limiting bacteremia. These new mAbs show promise as new S. suis diagnostic tools, as well as potential for therapeutic applications.Keywords
Funding Information
- International Development Research Centre (109047)
- Natural Sciences and Engineering Research Council of Canada (342150, 04435)
- Canadian Glycomics Network (TP-6)
- Fonds de Recherche du Québec - Nature et Technologies (2018-PR-206110)
This publication has 66 references indexed in Scilit:
- Fine specificity and cross-reactions of monoclonal antibodies to group B streptococcal capsular polysaccharide type IIIVaccine, 2012
- A Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal Antibody Requires Fcγ Receptor III and Macrophages To Mediate Protection against Pneumococcal Pneumonia in MiceInfection and Immunity, 2012
- Minimization of Bacterial Size Allows for Complement Evasion and Is Overcome by the Agglutinating Effect of AntibodyCell Host & Microbe, 2011
- The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophagesVaccine, 2010
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Aggregation of Streptococcus pneumoniae by a Pneumococcal Capsular Polysaccharide-Specific Human Monoclonal IgM Correlates with Antibody Efficacy In VivoClinical and Vaccine Immunology, 2010
- IgM in microbial infections: Taken for granted?Immunology Letters, 2009
- Efficacy of Opsonic and Nonopsonic Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal Antibodies against Intranasal Challenge withStreptococcus pneumoniaein MiceInfection and Immunity, 2009
- Vaccination of BALB/c Mice withEscherichia coli-Expressed Vaccinia Virus Proteins A27L, B5R, and D8L Protects Mice from Lethal Vaccinia Virus ChallengeJournal of Virology, 2008
- LAMP proteins are required for fusion of lysosomes with phagosomesThe EMBO Journal, 2007